Phase II Dose Selection for Alpha Synuclein–Targeting Antibody Cinpanemab (BIIB054) Based on Target Protein Binding Levels in the Brain

por Kuchimanchi, Mita, Monine, Michael, Kandadi Muralidharan, Kumar, Woodward, Caroline, Penner, Natalia
Publicado 2020

Population pharmacokinetics and standard uptake value ratio of aducanumab, an amyloid plaque–removing agent, in patients with Alzheimer’s disease

por Kandadi Muralidharan, Kumar, Tong, Xiao, Kowalski, Kenneth G., Rajagovindan, Raj, Lin, Lin, Budd Haberlain, Samantha, Nestorov, Ivan
Publicado 2021

Quantitative systems pharmacology model for Alzheimer’s disease to predict the effect of aducanumab on brain amyloid

por Lin, Lin, Hua, Fei, Salinas, Cristian, Young, Carissa, Bussiere, Thierry, Apgar, Joshua F., Burke, John M., Kandadi Muralidharan, Kumar, Rajagovindan, Rajasimhan, Nestorov, Ivan
Publicado 2022